医学
化脓性汗腺炎
痤疮
流行病学
置信区间
门诊部
优势比
人口
年轻人
皮肤病科
儿科
疾病
内科学
环境卫生
作者
Danchen Hu,Dorra Bouazzi,Cecilia E. Medianfar,Robin Christensen,Gregor B. E. Jemec,Songmei Geng
出处
期刊:Dermatology
[Karger Publishers]
日期:2024-12-20
卷期号:: 1-6
摘要
Background: Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent, and inflammatory disease. HS is fairly rare among the population. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to establish the prevalence of HS, based on a questionnaire and subsequent clinical examination targeting healthy adults accompanying patients undergoing care in a tertiary hospital. Objective and Methods: This study was a monocenter study in tertiary care in, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China, and was conducted by the Department of Dermatology. Healthy adults accompanying a patient to the outpatient clinic or hospitalized (Department of Dermatology excluded) were approached and surveyed after agreeing to participation. The data were collected by residents and students and the questionnaire was translated into Chinese. Results: A total of 552 Chinese participants were eligible for inclusion, consisting of 246 males and 306 females. A total of 515 participants were screened negative through the questionnaire. Twenty-two of the participants screened positive. Of these, four participants who were highly suspected to have HS declined a physical exam. The possibility of HS was ruled out by the collection of detailed medical histories of other participants (n = 16) screened positive. The confirmed prevalence of HS in the remaining 552 participants was 0.36% (95% confidence interval 0.10%–1.31%). Two participants, one male and one female, respectively, were diagnosed with HS. There were no significant differences in the median age, BMI and the percentage of smokers between the control group and the HS group. Conclusion: The estimated adult HS prevalence rate in Xi’an, China is 0.36%.
科研通智能强力驱动
Strongly Powered by AbleSci AI